Canton Strategic Holdings Inc (CNTN) Stock Analysis & Investment Frameworks

Canton Strategic Holdings Inc (CNTN) stock analysis on Invetso. Review Canton Strategic Holdings Inc’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Canton Strategic Holdings Inc Company Overview

Canton Strategic Holdings Inc Key Financial Metrics

About Canton Strategic Holdings Inc

Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.

Canton Strategic Holdings Inc Investment Frameworks

Invetso analyzes Canton Strategic Holdings Inc (CNTN) across the following frameworks:

Explore More CNTN Research